{{Drugbox
| verifiedrevid = 456081350
| IUPAC_name = ''N''-(1-azabicyclo[2.2.2]octan-8-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide
| image = Azasetron.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|azasetron}}
| pregnancy_category =  
| legal_status =  
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  90%
| metabolism =  
| elimination_half-life =  
| excretion =  60-70%

<!--Identifiers-->
| CAS_number = 123039-99-6
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 2264
| IUPHAR_ligand = 2285
| ChEMBL = 1598608
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 77HC7URR9Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07481

<!--Chemical data-->
| C=17 | H=20 | Cl=1 | N=3 | O=3 
| molecular_weight = 349.81 g/mol
| smiles = CN1C(=O)COC2=C1C=C(C=C2C(=O)NC3CN4CCC3CC4)Cl
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2177
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H20ClN3O3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13H,2-5,8-9H2,1H3,(H,19,23)
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WUKZPHOXUVCQOR-UHFFFAOYSA-N
|drug_name=|alt=|caption=|type=|MedlinePlus=|licence_EU=|pregnancy_AU=|pregnancy_US=|licence_US=|DrugBank=}}

'''Azasetron''' is an [[antiemetic]] which acts as a [[5-HT3 antagonist|5-HT<sub>3</sub> receptor]] [[receptor antagonist|antagonist]], pK<sub>i</sub> = 9.27 <ref>{{Cite web|url=http://drugcentral.org/drugcard/267/view?q=azasetron|title=Azasetron|last=|first=|date=2016-07-31|website=http://drugcentral.org/|publisher=UNM School of Medicine|access-date=2016-11-11}}</ref> It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as [[cisplatin]] chemotherapy). Azasetron hydrochloride is given in a usual dose of 10&nbsp;mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by [http://www.torii.co.jp/en/ Torii Pharmaceutical Co., Ltd.] under the trade names "Serotone® I.V. Injection 10 mg" and "Serotone® Tablets 10 mg".<ref>{{Cite web|url=http://www.torii.co.jp/en/ir/releases/20090113.html|title=Torii Pharmaceutical to Solely Market Antiemetic Drugs|last=|first=|date=2009-01-13|website=|publisher=Torii Pharmaceutical Co Ltd|access-date=2016-11-11}}</ref>  Pharmacokinetics data from S. Tsukagoshi.<ref>{{Cite journal|last=Tsukagoshi|first=S.|date=1999-06-01|title=[Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]|journal=Gan to Kagaku Ryoho. Cancer & Chemotherapy|volume=26|issue=7|pages=1001–1008|issn=0385-0684|pmid=10396331}}</ref>

'''References'''{{Reflist|2}}

<nowiki/>{{Serotonergics}}

[[Category:5-HT3 antagonists]]
[[Category:Morpholines]]
[[Category:Quinuclidines]]
[[Category:Lactams]]
[[Category:Chloroarenes]]
[[Category:Carboxamides]]


{{gastrointestinal-drug-stub}}